abstract
- Filippatos G, Butler J, Farmakis D, et al. Empagliflozin for heart failure with preserved left ventricular ejection fraction with and without diabetes. Circulation. 2022;146:676-86. 35762322.
In HFpEF, the benefit of empagliflozin on a composite of CV death or HF hospitalization at 26 mo did not vary by diabetes status
Journal Articles
- Overview
- Research
- Identity
- Additional Document Info
- View All
Overview
authors
status
publication date
- October 2022
has subject area
- 1103 Clinical Sciences (FoR)
- 1117 Public Health and Health Services (FoR)
- Benzhydryl Compounds (MeSH)
- Diabetes Mellitus (MeSH)
- Glucosides (MeSH)
- Heart Failure (MeSH)
- Hospitalization (MeSH)
- Humans (MeSH)
- Stroke Volume (MeSH)
- Ventricular Function, Left (MeSH)
published in
- ACP journal club Journal